
CLAIMS

1. Use of the ProTide compound CPF-373 having the structure:



, in the manufacture of a medicament for the adjuvant or neoadjuvant treatment of cancer by targeting cancer stem cells.

2. The use according to claim 1, wherein the treatment is of a human patient.

3. The use according to claim 1 or 2, wherein the cancer is selected from the group consisting of: leukaemia, lymphoma, multiple myeloma, lung cancer, liver cancer, breast cancer, head and neck cancer, neuroblastoma, thyroid carcinoma, skin cancer (including melanoma), oral squamous cell carcinoma, urinary bladder cancer, Leydig cell tumour, biliary cancer, such as cholangiocarcinoma or bile duct cancer, pancreatic cancer, colon cancer, colorectal cancer and gynaecological cancers, including ovarian cancer, endometrial cancer, fallopian tube cancer, uterine cancer and cervical cancer, including epithelia cervix carcinoma.

4. The use according to claim 3, wherein the cancer is leukaemia selected from the group consisting of acute lymphoblastic leukaemia, acute myelogenous leukaemia (also known as acute myeloid leukaemia or acute non-lymphocytic leukaemia), acute promyelocytic leukaemia, acute lymphocytic leukaemia, chronic myelogenous leukaemia (also known as chronic myeloid leukaemia, chronic myelocytic leukaemia or chronic granulocytic leukaemia), chronic lymphocytic leukaemia, monoblastic leukaemia and hairy cell leukaemia.


5. The use according to claim 3, wherein the cancer is lymphoma selected from the group consisting of: Hodgkin’s lymphoma; non-Hodgkin lymphoma; Burkitt’s lymphoma; and small lymphocytic lymphoma.

6. The use according to any preceding claim, wherein the targeting of cancer stem cells causes their death.


7. The use according to any preceding claim, wherein the treatment of cancer is by (i) reducing or preventing cancer development; (ii) reducing or preventing cancer progression; (iii) reducing or preventing cancer recurrence; or (iv) reducing or preventing cancer propagation.

8. The use according to any preceding claim, wherein the cancer is a relapsed or refractory cancer.


9. A compound selected from: CPF447, CPF727, CPF544, CPF680, CPF545, and CPF682, or a pharmaceutically acceptable salt thereof, wherein CPF447, CPF727, CPF544, CPF680, CPF545, and CPF682 have the following structures:




(CPF447);




(CPF727);




(CPF544);



(CPF 680);




(CPF545); and




(CPF 682).


10. A pharmaceutical formulation comprising a compound selected from: CPF447, CPF727, CPF544, CPF680, CPF545 and CPF682, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient, wherein CPF447, CPF727, CPF544, CPF680, CPF545, and CPF682 have the following structures:




(CPF447);




(CPF727);




(CPF544);



(CPF 680);



(CPF545); and



(CPF 682).